MeiraGTx (NASDAQ:MGTX – Get Free Report) and Xenetic Biosciences (NASDAQ:XBIO – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, dividends, valuation and earnings.
Profitability
This table compares MeiraGTx and Xenetic Biosciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| MeiraGTx | 19.87% | 283.85% | 29.39% |
| Xenetic Biosciences | -75.90% | -40.62% | -34.97% |
Analyst Recommendations
This is a summary of recent ratings for MeiraGTx and Xenetic Biosciences, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| MeiraGTx | 0 | 3 | 5 | 1 | 2.78 |
| Xenetic Biosciences | 1 | 0 | 0 | 0 | 1.00 |
Valuation and Earnings
This table compares MeiraGTx and Xenetic Biosciences”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| MeiraGTx | $397.50 million | 2.54 | -$114.20 million | $0.71 | 14.79 |
| Xenetic Biosciences | $3.26 million | 1.49 | -$2.68 million | ($1.16) | -1.83 |
Xenetic Biosciences has lower revenue, but higher earnings than MeiraGTx. Xenetic Biosciences is trading at a lower price-to-earnings ratio than MeiraGTx, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
MeiraGTx has a beta of 1.35, meaning that its share price is 35% more volatile than the S&P 500. Comparatively, Xenetic Biosciences has a beta of 2.19, meaning that its share price is 119% more volatile than the S&P 500.
Insider & Institutional Ownership
67.5% of MeiraGTx shares are held by institutional investors. Comparatively, 15.1% of Xenetic Biosciences shares are held by institutional investors. 7.4% of MeiraGTx shares are held by company insiders. Comparatively, 7.6% of Xenetic Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Summary
MeiraGTx beats Xenetic Biosciences on 12 of the 15 factors compared between the two stocks.
About MeiraGTx
MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.
About Xenetic Biosciences
Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.
Receive News & Ratings for MeiraGTx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MeiraGTx and related companies with MarketBeat.com's FREE daily email newsletter.
